Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft

Cancer Letters

Volumn 312, Issue 1, 2011, Pages 109-116

  Fu, Xian hua ^a   Li, Jun ^a   Zou, Yong ^b   Hong, Yu rong ^c   Fu, Zhi xuan ^a   Huang, Jian jin ^a   Zhang, Su zhan ^a   Zheng, Shu ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b GUANGZHOU INSTITUTE OF CHEMISTRY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Anti angiogenesis agent; Combretastatin A4 phosphate; Endostar; Osteosarcoma; Vascular disrupting agent

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; DOXORUBICIN; ENDOSTAR; RECOMBINANT ENDOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG TOXICITY; MOUSE; NEPHROTOXICITY; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; DRUG SYNERGISM; ENDOSTATINS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OSTEOSARCOMA; RANDOM ALLOCATION; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053333348     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.008     Document Type: Article

References (30)

1. Griggs J., Metcalfe J.C., Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol. 2001, 2:82-87.
2. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390:404-407.
3. Delmonte A., Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin. Investig. Drugs 2009, 18:1541-1548.
4. Tozer G.M., Kanthou C., Baguley B.C. Disrupting tumour blood vessels. Nat. Rev. Cancer 2005, 5:423-435.
5. Yeung S.C., She M., Yang H., Pan J., Sun L., Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 2007, 92:2902-2909.
6. Nagaiah G., Remick S.C. Combretastatin A4 phosphate: a novel vascular disrupting agent. Future Oncol. 2010, 6:1219-1228.
7. West C.M., Price P. Combretastatin A4 phosphate. Anticancer Drugs 2004, 15:179-187.
8. Ling Y., Yang Y., Lu N., You Q.D., Wang S., Gao Y., Chen Y., Guo Q.L. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem. Biophys. Res. Commun. 2007, 361:79-84.
9. Zhuo W., Luo C., Wang X., Song X., Fu Y., Luo Y. Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells. J. Pathol. 2010, 222:249-260.
10. Song H.F., Liu X.W., Zhang H.N., Zhu B.Z., Yuan S.J., Liu S.Y., Tang Z.M. Pharmacokinetics of His-tag recombinant human endostatin in Rhesus monkeys. Acta Pharmacol. Sin. 2005, 26:124-128.
11. Jiang L.P., Zou C., Yuan X., Luo W., Wen Y., Chen Y. N-terminal modification increases the stability of the recombinant human endostatin in vitro. Biotechnol. Appl. Biochem. 2009, 54:113-120.
12. Ducki S., Mackenzie G., Greedy B., Armitage S., Chabert J.F., Bennett E., Nettles J., Snyder J.P., Lawrence N.J. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: structure-based discovery of alpha-aryl chalcones. Bioorg. Med. Chem. 2009, 17:7711-7722.
13. Liou J.P., Chang Y.L., Kuo F.M., Chang C.W., Tseng H.Y., Wang C.C., Yang Y.N., Chang J.Y., Lee S.J., Hsieh H.P. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J. Med. Chem. 2004, 47:4247-4257.
14. Young S.L., Chaplin D.J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin. Investig. Drugs 2004, 13:1171-1182.
15. Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., Barber P.R., Vojnovic B., Chaplin D.J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001, 61:6413-6422.
16. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 1997, 57:1829-1834.
17. Beauregard D.A., Thelwall P.E., Chaplin D.J., Hill S.A., Adams G.E., Brindle K.M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Brit. J. Cancer 1998, 77:1761-1767.
18. Nam N.H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem. 2003, 10:1697-1722.
19. Pedley R.B., Hill S.A., Boxer G.M., Flynn A.A., Boden R., Watson R., Dearling J., Chaplin D.J., Begent R.H. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 2001, 61:4716-4722.
20. Mitrus I., Sochanik A., Cichon T., Szala S. Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochim. Pol. 2009, 56:161-165.
21. Meyer T., Gaya A.M., Dancey G., Stratford M.R., Othman S., Sharma S.K., Wellsted D., Taylor N.J., Stirling J.J., Poupard L., Folkes L.K., Chan P.S., Pedley R.B., Chester K.A., Owen K., Violet J.A., Malaroda A., Green A.J., Buscombe J., Padhani A.R., Rustin G.J., Begent R.H. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. Clin. Cancer Res. 2009, 15:4484-4492.
22. Siemann D.W., Chaplin D.J., Walicke P.A. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin. Investig. Drugs 2009, 18:189-197.
23. Siemann D.W., Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008, 28:2027-2031.
24. Hori K. Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy 2005, 51:357-360.
25. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., Hicklin D.J., Chaplin D., Foster F.S., Benezra R., Kerbel R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
26. Ferrari S., Smeland S., Mercuri M., Bertoni F., Longhi A., Ruggieri P., Alvegard T.A., Picci P., Capanna R., Bernini G., Muller C., Tienghi A., Wiebe T., Comandone A., Bohling T., Del P.A.B., Brosjo O., Bacci G., Saeter G. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J. Clin. Oncol. 2005, 23:8845-8852.
27. Giantonio B.J., Catalano P.J., Meropol N.J., O'Dwyer P.J., Mitchell E.P., Alberts S.R., Schwartz M.A., Benson A.B. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 2007, 25:1539-1544.
28. Gaya A., Daley F., Taylor N.J., Tozer G., Qureshi U., Padhani A., Pedley R.B., Begent R., Wellsted D., Stirling J.J., Rustin G. Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study. Brit. J. Cancer 2008, 99:321-326.
29. US National Institutes of Health, A Study to Assess The Effectiveness of The Combination of Carboplatin, Paclitaxel, Bevacizumab and Combretastatin (CA4P) in Patients with Chemotherapy Naïve Lung Cancer. <> (accessed 17.08.09). http://clinicaltrials.gov/ct2/show/NCT00653939.
30. Rustin G.J., Galbraith S.M., Anderson H., Stratford M., Folkes L.K., Sena L., Gumbrell L., Price P.M. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 2003, 21:2815-2822.